Key facts
- It has raised $2.5M across 2 recorded rounds; the latest was Seed Round ($700K) in Jan 2026.
- Notable investors include United States Department of War, Elevate Ventures, BioCrossroads, Lung, National Heart — 6 tracked in total.
- Allinaire Therapeutics has filed 4 Form Ds with the SEC since 2016, most recently Apr 2026 ($700K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Allinaire Therapeutics
Funding rounds
2 roundsAbout Allinaire Therapeutics
Operator of a biotechnology company intended to develop novel therapeutics for cardiopulmonary diseases. The company develops a novel target to halt the progression of pulmonary arterial hypertension (PAH) and other pulmonary conditions, enabling the healthcare sector clients to offer treatment options with the potential to improve clinical outcomes for patients with PAH.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2011
- Employees
- 3
- Website
- allinaire.com/
- Ownership
- Privately Held (backing)
Allinaire Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allinaire Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allinaire Therapeutics in its N-PORT filings yet. We sweep new filings monthly.